abstract |
A RANKL-inhibitor for use in the treatment of a patient suffering from chemotherapy resistant cancer, which patient has a diagnosis of cancer that is unresponsive to treatment with a first chemotherapeutic agent, wherein said cancer is not a solid tumor or metastasis in the bone, and said patient is administered a second chemotherapeutic agent in combination with said RANKL-inhibitor. |